US Flies B-1B Bomber Over Korean Peninsula: What It Means For Defense Companies, ETFs
B-1B bomber dropped JDAMs while being escorted by South Korean jets. Both were manufactured by Boeing.
Amazon Vs. Walmart: Who Will Be The First To Conquer The Skies With Drone Delivery?
Amazon and Walmart, the two largest American online retailers, are competing to conquer the skies with their drone delivery services.
Bath & Body Works To See More Comfort In Second Half Numbers With Further Improvement: Analysts
Analysts foresee Bath & Body Works' second-half performance improving, citing strength in product innovation and category expansion, despite inventory uptick in Q1 FY24.
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key secondary endpoints were met with no new safety signals.
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.
Proto Labs Positioned For Growth: Analyst Predicts Strong Gains Amid Digital Manufacturing Surge
Analyst initiates coverage on Proto Labs with Overweight rating and $44.00 price target. Company well-positioned in growing digital manufacturing market.
Medtronic Recalls Some Versions Of Software Used For Cranial Surgery
Medtronic is recalling specific StealthStation S8 application versions due to a serious software error affecting surgical navigation displays. Medtronic is providing a free software update to fix the problem.
What’s Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.
Tesla’s FSD Subscribers Halt Subscriptions Over Lack of New Software Features
Tesla's (NASDAQ: TSLA) latest Full Self-Driving (FSD) updates, V12.3 and V12.4, have left some subscribers frustrated.
These updates are built on older base software versions. That means customers are paying $99/month for FSD are not receiving the latest software feature improvements.
Looking Into CACI International’s Recent Short Interest
CACI International’s (NYSE:CACI) short percent of float has fallen 7.81% since its last report. The company recently reported…